CUSIP: 03835L207
Q3 2023 13F Holders as of 30 Sep 2023
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
3,409,316
-
Share change
-
+2,480,512
-
Total reported value
-
$1,125,754
-
Price per share
-
$0.33
-
Number of holders
-
26
-
Value change
-
+$789,583
-
Number of buys
-
9
-
Number of sells
-
7
Quarterly Holders Quick Answers
What is CUSIP 03835L207?
CUSIP 03835L207 identifies APVO - APTEVO THERAPEUTICS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q4 2023
-
Previous quarter:
Q2 2023
Recent filing periods for CUSIP 03835L207:
Institutional Holders of APTEVO THERAPEUTICS INC - COM NEW (APVO) as of Q3 2023
As of 30 Sep 2023,
APTEVO THERAPEUTICS INC - COM NEW (APVO) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,409,316 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, ARMISTICE CAPITAL, LLC, VANGUARD GROUP INC, RENAISSANCE TECHNOLOGIES LLC, Schonfeld Strategic Advisors LLC, GEODE CAPITAL MANAGEMENT, LLC, CANTOR FITZGERALD, L. P., BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, and NORTHERN TRUST CORP.
This page lists
26
institutional shareholders reporting positions in this security
for the Q3 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.